RANI
Rani Therapeutics Holdings, Inc.
3.25
USD
This page is just a preview of the data found in TrendSpider’s full version
Rani Therapeutics Holdings, Inc. stock is up 64.14% since 30 days ago. The next earnings date is Mar 20, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 33.33% of the previous 2 December’s closed higher than November. 100% of analysts rate it a buy.
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly. RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis, RT-102, a parathyroid hormone that is in preclinical studies for osteoporosis.
